drugset / Trial / NCT02433795
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Phase 2
Completed
27 enrolled
Seoul National University Hospital
Chonbuk National University Hospital · collabChungnam National University · collabGachon University Gil Medical Center · collabGangnam Severance Hospital · collabGyeongsang National University Hospital · collabHallym University Medical Center · collabInje University · collabKorea Cancer Center Hospital · collabSeoul National University Boramae Hospital · collabSeoul National University Bundang Hospital · collabThe Catholic University of Korea · collabWonju Severance Christian Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will be conducted to evaluate the efficacy of Bendamustine Plus Rituximab (BR) in patients with relapsed or progressive Marginal Zone B-cell Lymphoma (MZBCL).
Timeline
- Start
- 2015-05
- Primary completion
- 2019-10
- Completion
- 2019-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 90 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 1400 mg | Intravenous |